Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis
Journal of Clinical Medicine · 29.01.2024 · 13 (3) · 766
DOI: 10.3390/jcm13030766 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 29.01.2024. Verfasst von Giuseppe Cuccia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, L. Go A. Gemelli 8, 00168 Rome, Italy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Personalised medicine and the identification of predictors of the efficacy of specific drugs represent the ultimate goal for the treatment of ulcerative colitis (UC) in order to break the current therapeutic ceiling. JAK inhibitors are a new class of advanced therapies, orally administered, showing a good profile of efficacy and safety in both randomised controlled trials (RCTs) and real-world studies. Unfortunately, to date, it is not possible to draw the ideal profile of a patient maximally benefiting from this class of drugs to guide clinicians’ therapeutic choices. Baseline clinical activities and inflammatory biomarkers, as well as their early variation after treatment initiation, emerged as the main predictors of efficacy from post hoc analyses of RCTs with tofacitinib. Similar findings were also observed in the real-life studies including mainly patients with a history of pluri-refractoriness to biological therapies. At last, a few new biomarkers have been explored, even though they have not been validated in large cohorts. This paper provides a review of the current knowledge on clinical variables and biomarkers predicting response to JAK inhibitors in UC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, L. Go A. Gemelli 8, 00168 Rome, Italy.
- Dipartimento di Scienze della Salute, Università degli Studi di Milano, 20122 Milan, Italy.
- IBD UNIT-CEMAD (Centro Malattie Apparato Digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, 00168 Rome, Italy.
- UOC Pronto Soccorso, Medicina d'Urgenza e Medicina Interna, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy.
- UOS Gastroenterologia, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy.
ORCID-Profile: Franco Scaldaferri, Daniela Pugliese
Zitieren
APA
Cuccia, G., Privitera, G., Di Vincenzo, F., Monastero, L., Parisio, L., Carbone, L., Scaldaferri, F., & Pugliese, D. (2024). Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis. Journal of Clinical Medicine, 13(3), 766. https://doi.org/10.3390/jcm13030766
Vancouver
Cuccia G, Privitera G, Di Vincenzo F, Monastero L, Parisio L, Carbone L, et al. Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis. Journal of Clinical Medicine. 2024;13(3):766. doi:10.3390/jcm13030766
BibTeX
@article{Cuccia2024,
author = {Cuccia, Giuseppe and Privitera, Giuseppe and Di Vincenzo, Federica and Monastero, Lucia and Parisio, Laura and Carbone, Luigi and Scaldaferri, Franco and Pugliese, Daniela},
title = {Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {3},
pages = {766},
doi = {10.3390/jcm13030766}
}
EUVIMED